Special items: Ovarian Cancer and Us blog best viewed in Firefox

▼
Showing posts with label phase 11. Show all posts
Showing posts with label phase 11. Show all posts
Wednesday, May 09, 2012

Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA - News

›
Rexahn Pharmaceuticals Submits Archexin Phase II Protocol for Ovarian Cancer to FDA May 08, 2012 08:03 AM Eastern Daylight Time  ROCKV...
Monday, March 12, 2012

phase 11/111 - Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov

›
Comparing Three Combination Chemotherapy Regimens in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial ...
Sunday, March 11, 2012

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

›
A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites Objective  The reco...
Friday, February 17, 2012

Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a California cancer consortium study.

›
Phase II trial of bryostatin-1 in combination with cisplatin in patients with recurrent or persistent epithelial ovarian cancer: a Californi...
Wednesday, July 06, 2011

abstract: Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A phase II study

›
CONCLUSION: Sorafenib fails to achieve sufficient objective response or sustained disease stabilization as third-line treatment for EOC.
Monday, March 21, 2011

press release/abstract: Marshall Edwards Announces Publication of Phase II Clinical Trial Results - Phenoxodiol phase 11 ovarian cancer trial results (32 pts)

›
SAN DIEGO , March 21, 2011 / PRNewswire / -- Marshall Edwards , Inc.(Nasdaq: MSHL ), an oncology company focused on the clinical develo...
1 comment:
Wednesday, March 09, 2011

abstract: A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: (GOG 146Q)

›
Monday, September 06, 2010

Oncolytics Biotech(R) Inc. Announces Randomized Phase II Ovarian Cancer Study to be Conducted by the Gynecologic Oncology Group and Sponsored by the National Cancer Institute

›
Press Release : Sept. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY) announced today t...
Monday, August 16, 2010

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study

›
Results: Of 30 eligible patients, most had serous histology (67%), were platinum sensitive (73%) and had two prior chemotherapies ...
Wednesday, August 11, 2010

phase 11 - RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov (location: PMH Toronto)

›
This study is not yet open for participant recruitment. Verified by National Cancer Institute (NCI), August 2010 Purpose RATION...
Tuesday, August 03, 2010

Curis (financial news) - phase 11 advanced ovarian cancer results Aug 2010 (hedgehog pathway inhibitor)

›
CAMBRIDGE, Mass., Aug 03, 2010 (BUSINESS WIRE) -- Curis, Inc. /quotes/comstock/15*!cris/quotes/nls/cris (CRIS 1.75, -0.02, -1.13%) , a dru...
Wednesday, June 16, 2010

PharmaLive: Curis / GDC-0449 [phase 11 trial results to follow

›
Note :  excerpt - Avastin + chemo "Genentech and Roche are also conducting a randomized double-blind placebo-controlled Phase II tria...
Tuesday, May 11, 2010

ASCO - Endocyte Officials to Present Results from Four Clinical Trials at ASCO Annual Meeting - PRECEDENT = EC145/platinum resistant ovarian

›
"Interim results from the PRECEDENT study, a randomized phase II study of the combination of EC145 and Doxil for the treatment of patie...
Friday, January 22, 2010

Maintenance immunotherapy in recurrent ovarian cancer: Long term follow-up of a phase II study

›
"Therapy consisted of low-dose subcutaneous IL-2 and oral RA, administered on intermittent schedules for up to 5 years."